Novo Nordisk (NVO) has filed suit against a string of medical spas and wellness clinics for allegedly selling generic versions of its blockbuster semaglutide (GLP) weight-loss drugs Ozempic and Wegovy.
The generic versions of these medications do not necessarily follow the exact specifications of the Novo Nordisk brands, which the company said could make them hazard to human health.
Sales of GLP medications have skyrocketed as demand has outstripped supply, leading to drug shortages.
Recently, the Food and Drug Administration (FDA) warned consumers not to use these off-brand versions.
The World Health Organization (WHO) has also cautioned against these weight-loss medications, stressing that they are no substitute for sound diet and exercise programs.